Main Menu
MSAA
  • Toll-Free Helpline Call Us Toll Free (800) 532-7667 Search
  • Get MS Updates
  • Información en Español
  • Donate
  • Skip main navigation
MSAA logo
  • MS Information
    • MS Overview & Glossary
    • Newly Diagnosed
    • Symptoms
    • Treatments
    • COVID-19 and MS
    • Patient Support Programs
    • Clinical Trials Search
    • Publications
    • Latest News from MSAA
    • Videos and Webinars
    • Podcasts from MSAA
    • Toll-free Helpline & Chat
    • Información en Español
    • MS FAQs and Glossary
  • How MSAA Can Help
    • Toll-free Helpline & Chat
    • Publications
    • Videos and Webinars
    • Cooling Products
    • Equipment Products
    • MRI Access Program
    • Educational Programs
    • Shared Decision-Making Tools
    • Overall Wellness
    • Online Aquatic Center
    • FAQs
  • Living with MS
    • My MSAA Community
    • MS Conversations Blog
    • Multiple Sclerosis Implementation Network™ (MSIN™)
    • My MS Journey
    • My MS Manager™ Mobile App
    • MS Relapse Resource Center
    • Overall Wellness
    • Online Aquatic Center
    • Educational Programs
  • Donate
    • Make A Donation
    • Honor and Memorial Donations
    • Become a Monthly Improver
    • Planned Giving
    • Other Ways to Give
      • Donor-Advised Funds
      • Vehicle Donation
      • Matching Gifts
      • Shop & Support MSAA
    • Donation FAQs
  • Get Involved
    • Special Events
    • Art Showcase
    • Do-It-Yourself Fundraiser
    • Multiple Sclerosis Implementation Network™ (MSIN™)
    • Partnerships
    • Volunteer With MSAA
    • FAQ
  • Calendar
  • About MSAA
    • Mission and Overview
    • MS Awareness Month
    • MSAA Achievements
    • Contact Us
    • Board of Directors
    • Healthcare Advisory Council
    • African American Advisory Board
    • Hispanic/Latinx Advisory Board
    • MSAA Strategic Plan
    • Navigating MS
    • MS Coalition
    • Annual Report
    • Financial Information
  • Search
  • Home
  • Tysabri®
Back to Treatment Guide

Tysabri®

natalizumab

Quick Facts

Tysabri® is a synthetic monoclonal antibody that prevents harmful cells from entering the central nervous system.

In-clinic intravenous infusion

Every four weeks

Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS

Potential Benefit:

Over 2 years Tysabri® compared to placebo:

  • Decreased the number of relapses by 67%
  • On MRI, reduced lesions by 92% new active inflammation
  • Reduced disability progression by 42% over 3 months
  • Reduced disability progression by 54% over 6 months

Common Potential Side Effects

Headache and fatigue, infections like upper respiratory tract infection or urinary tract infection (UTI), infusion reactions

Prescription Assistance:

Biogen Support Services >

For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.


NATALIZUMAB BIOSIMILAR

Tyruko® (natalizumab-sztn)

Tyruko® (natalizumab-sztn), a biosimilar to natalizumab (Tysabri®), was approved by the FDA in August 2023. A biosimilar is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA. Approved to treat relapsing forms of MS, Tyruko is given at the same dosage and via the same administration as Tysabri, while also carrying the same benefits and risks.


Hear from the Expert
Heidi Crayton, MD
Medical Director, MS Center of Greater Washington
Heidi Crayton, MD
“I think it’s important that patients understand the mechanism of action.”

DRUGMAKER

Biogen

HOW Tysabri® WORKS

Tysabri is believed to prevent harmful inflammatory immune cells from crossing into the central nervous system (CNS). This may reduce damage and inflammation that relapsing MS causes in the central nervous system.

FDA-Approved

Tysabri was FDA-approved in 2004 but left the market and was reintroduced in 2006 as monotherapy to treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS.

Potential Side Effects

Headache, fatigue, depression, joint pain, abdominal discomfort, and infection. Risk of infection, including pneumonia, was the most common serious adverse event during the studies (occurring in a small percentage of people). A less common serious side effect is progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually leads to death or severe disability over a period of weeks or months.

OTHER KEY INFORMATION

  • Frequency of visits determined by your healthcare provider
  • Required enrollment in the TOUCH prescribing program, and recertification every 6 months

Regular testing completed after starting Tysabri® include:

  • Baseline brain MRI and follow-up
  • Complete Blood Count (CBC)
  • Liver enzymes
  • John Cunningham virus (JCV) antibodies
  • Routine follow-up

Patient advocates talk about
their treatment experience

  • Kristie Salerno Kent
    MS Advocate, Patient Advocacy Consultant
    Kristie Salerno Kent
    “I have had situations where treatments aren’t approved at first. My doctors, nurses, they actually go to bat for me and made it happen.”
  • Azure Antoinette
    MS Advocate
    Azure Antoinette
    "I will be undergoing my first disease-modifying therapy to help treat multiple sclerosis in my body and while I’m very nervous, I am equally as excited and looking forward to the positive effects of how I will feel physically, and mentally, and emotionally."
  • Damian Washington
    MS Advocate
    Damian Washington
    “Nobody’s going to be looking out for your best interests better than you.”
  • Cathy Chester
    MS Advocate
    Cathy Chester
    “I think it’s really important to talk about how to age with this illness.”
  • Lauren Hutton-Work
    MS Advocate
    Lauren Hutton-Work
    “Just because you have this disease does not mean that your work life should be awkward or uncomfortable.”
  • Chernise Joseph
    MS Advocate
    Chernise Joseph
    “My first neurologist was a frontline neurologist, he wasn’t an MS specialist.”
  • Julian Gamboa
    MS Advocate
    Julian Gamboa
    “If you’re newly diagnosed with multiple sclerosis remember it’s always okay to get a second opinion.”
  • Lauren and Sam Alcorn
    MS Advocates
    Lauren and Sam Alcorn
    “Our future is uncertain and we have to enjoy each other and love each other in the present.”
  • Shawn Feliciano
    MS Advocate
    Shawn Feliciano
    “I want to know what medications might work best for someone who’s Hispanic.”
  • Darlene Feigen
    MS Advocate
    Darlene Feigen
    “The sooner you get on a therapy the better it is in the long run.”
  • Birgit Bauer
    MS Advocate
    Birgit Bauer
    “At the end of the appointment you should have an answer to the most important questions.”
  • Ellen Tutton
    MS Advocate
    Ellen Tutton
    “I looked up all the different disease-modifying therapies and compared them to my lifestyle.”
  • Victoria Marie Reese
    MS Advocate
    Victoria Marie Reese
    “I’m trying to show my daughter that taking care of yourself is cool.”
    • MSAA logo
    • (800) 532-7667
    • msaa@mymsaa.org
    • MSAA is a 501(C)(3) nonprofit registered in the US under EIN: 22-1912812.Copyright ©2025 Multiple Sclerosis Association of America.Reproduction of material from any mymsaa.org pages without written permission is strictly prohibited.
    • GET EMAIL UPDATES
    • Privacy Policy and Terms of Use
    • Donor Privacy Policy
    • Financial Information
    • Información en Español
    • Contact Us
    • GET SMS UPDATES:
      Text
      MSAA to 75101

       
      Why sign up?
      You’ll get important MS-related news, crucial updates about our programs, and easy ways to support the MS community right from your phone.
       
      By participating, you agree to the terms and privacy policy for recurring autodialed campaign & donation messages from MSAA to the phone number you provide. No consent required to buy. Message and data rates may apply.
    • Guidestar Logo
    • Charity Navigator
    • America's Charities
    • Facebook
    • Twitter
    • Instagram
    • Tik Tok
    • Pinterest
    • YouTube
    • LinkedIn
    • ESSENTIAL
    • Accessibility Statement

Oct 2, 2023 @ 3:19 pm

×